ClinicalTrials.gg
RecruitingNCT07672899Updated Jun 29, 2026

Small RNA tRF-31 Changes in Patients With Age-Related Cataract

An observational study in Cataract, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Cataract by Second Affiliated Hospital, School of Medicine, Zhejiang University — 6 open to participants now, 6 under way, none of them phase 3. Cataract · Second Affiliated Hospital, School of Medicine, Zhejiang University.

Started
2026
the only one that year
Observational
2 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Cataract by Second Affiliated Hospital, School of Medicine, Zhejiang University, this one is the only one that started in 2026, is one of 2 observational ones, and was the 11th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

6 of the 11 studies in Cataract by Second Affiliated Hospital, School of Medicine, Zhejiang University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Cataract by Second Affiliated Hospital, School of Medicine, Zhejiang University, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluate the expression characteristics and clinical relevance of the tRF-31/HIPK2 signaling axis in adults over 18 years old with age-related cataract (ARC). The main questions it aims to answer are: Is there a correlation between the relative expression levels of tRF-31 and its target gene HIPK2 in the anterior lens capsule and the clinical severity (Emery-Little grading system) of age-related cataracts? Does oxidative stress in the anterior segment microenvironment have a potential bystander effect on the state of the corneal endothelium? Participants will:Undergo routine preoperative ophthalmologic examinations, including visual acuity tests, slit-lamp photography, and corneal endothelial cell counting. Undergo standard cataract surgery (phacoemulsification combined with intraocular lens implantation) as part of their regular medical care. Allow researchers to collect and analyze their anterior lens capsule tissue, which is routinely removed and typically discarded as medical waste during the standard continuous curvilinear capsulorhexis (CCC) step of the surgery.

03

Conditions studied

  • Cataract

Browse trials for

Keywords

  • age-related cataract
  • oxidative stress
  • tRNA-derived small RNA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population consists of adult patients over 18 years of age who have been clinically diagnosed with age-related cataract (ARC) and are scheduled to undergo routine phacoemulsification combined with intraocular lens implantation at the Eye Center of the Second Affiliated Hospital, Zhejiang University School of Medicine.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients older than 18 years. Clinically diagnosed with age-related cataract (ARC) and have clear surgical indications for routine phacoemulsification combined with intraocular lens (IOL) implantation. Scheduled to undergo cataract extraction and intraocular lens implantation. Completed routine preoperative corneal endothelial specular microscopy, providing objective data including cell density, coefficient of variation of cell area, and the proportion of hexagonal cells. Provided signed written .

Exclusion criteria

Exclusion Criteria:

History of ocular trauma, glaucoma, episodes of active uveitis, or previous intraocular surgery. Presence of severe systemic diseases rendering the patient unsuitable for surgery. Poor patient compliance or coexisting psychiatric disorders. Severe systemic metabolic syndromes (e.g., diabetes). Diagnosis of high myopia. Current participation in other clinical trials or likelihood of being lost to follow-up.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Patient registry
No

Interventions

  • ProcedureBiospecimen collection (Anterior lens capsule)

    This is an observational study without investigational interventions. Participants will undergo standard-of-care phacoemulsification combined with intraocular lens implantation for age-related cataract. During the routine continuous curvilinear capsulorhexis (CCC) step of the surgery, the central anterior lens capsule, which is typically discarded as medical waste, will be collected for subsequent molecular analysis. This tissue collection relies entirely on the standard surgical procedure and does not alter the patient's routine clinical treatment pathway in any way.

06

What researchers measure

Primary outcomes

  1. Correlation between relative expression of tRF-31 and cataract nuclear hardness (Emery-Little grading system)

    Time frame: Baseline (Preoperative, up to 1 month prior to surgery)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Aug 2026, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jun 29, 2026
StartActual
Jun 17, 2026
Primary completionEst.
Aug 16, 2026
CompletionEst.
Sep 16, 2026
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07672899
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Jun 17, 2026
Primary completion
Aug 16, 2026 (estimated)
Completion
Sep 16, 2026 (estimated)
Last update
Jun 29, 2026

Study contacts

Yueyang Zhong
Contact
yyzbzhong@zju.edu.cn
+86+ 18868125901

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion